- US FDA approves Boehringer Ingelheim’s lung cancer treatment Reuters
- Top German Pharma Boehringer Wins US Approval for Cancer Drug Bloomberg.com
- FDA Grants Accelerated Approval to Zongertinib for Nonsquamous NSCLC With HER2 TKD Mutations OncLive
- Amol Akhade: Zongertinib – A New Targeted Therapy Option for a Rare Molecular Subset of Lung Cancer Oncodaily
- Boehringer Ingelheim breaks into oncology with FDA approval for lung cancer med Hernexeos Fierce Pharma
Source link
